CRISPR/Cas9- or Plecstatin-1 (PST)-mediated plectin inactivation attenuates hepatocellular carcinoma (HCC) oncogenic potential through FAK, Erk1/2, and PI3K/Akt axis. Here, AKT1 is linked to hepatocellular carcinoma.